These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
779 related articles for article (PubMed ID: 31486493)
1. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway. Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493 [TBL] [Abstract][Full Text] [Related]
2. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway. Gao BB; Wang SX Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077 [TBL] [Abstract][Full Text] [Related]
3. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway. Gong T; Cui L; Wang H; Wang H; Han N J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734 [TBL] [Abstract][Full Text] [Related]
4. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Cai Y; Dong ZY; Wang JY Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323 [TBL] [Abstract][Full Text] [Related]
5. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway. Shi H; Pu J; Zhou XL; Ning YY; Bai C Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375 [TBL] [Abstract][Full Text] [Related]
6. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling. Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094 [TBL] [Abstract][Full Text] [Related]
7. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2. He R; Liu H Gene; 2020 Jul; 747():144553. PubMed ID: 32165307 [TBL] [Abstract][Full Text] [Related]
8. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9. Liu B; Wang R; Liu H Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989 [TBL] [Abstract][Full Text] [Related]
9. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR. Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640 [TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA SNHG7 contributes to cell proliferation, migration, invasion and epithelial to mesenchymal transition in non-small cell lung cancer by regulating miR-449a/TGIF2 axis. Pang L; Cheng Y; Zou S; Song J Thorac Cancer; 2020 Feb; 11(2):264-276. PubMed ID: 31793741 [TBL] [Abstract][Full Text] [Related]
11. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway. Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322 [TBL] [Abstract][Full Text] [Related]
12. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer. Zhou Y; Li S; Li J; Wang D; Li Q Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819 [TBL] [Abstract][Full Text] [Related]
13. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer. Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469 [TBL] [Abstract][Full Text] [Related]
14. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer. Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838 [TBL] [Abstract][Full Text] [Related]
15. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression. Xia A; Li H; Li R; Lu L; Wu X Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933 [TBL] [Abstract][Full Text] [Related]
17. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression. Ju ZS; Sun B; Bao D; Zhang XF Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788 [TBL] [Abstract][Full Text] [Related]
18. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis. Huang Q; Xing S; Peng A; Yu Z Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841 [TBL] [Abstract][Full Text] [Related]
20. The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis. Chen L; Han X; Hu Z; Chen L Cancer Chemother Pharmacol; 2019 May; 83(5):921-931. PubMed ID: 30859368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]